Jennifer Esau
Family Medicine · Emporia, KSNPI 1154649044
Payments from drug & device makers
Across 197 payments — averaging $14.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$486
- Novo Nordisk$425
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$269
- Lilly USA, LLC$201
- AstraZeneca$192
- Amgen$177
- plus $1K from 29 others
What the payments were for
- Food & beverage$2,919100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$2,919 in reported general payments places this provider in the 80th percentile of 1,469 family medicine providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 41 | $43,272 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 21 | $29,590 |
| JanuviaSitagliptin Phosphate | 27 | $25,864 |
| JardianceEmpagliflozin | 46 | $24,545 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $23,259 |
| EliquisApixaban | 18 | $21,405 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $16,081 |
| TrulicityDulaglutide | 13 | $11,944 |
| OzempicSemaglutide | 12 | $11,391 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $11,325 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $11,229 |
| Repatha SureclickEvolocumab | 13 | $10,380 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $8,160 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 13 | $7,145 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $6,834 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $192 | $60,29171 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $23 | $29,80147 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $71 | $29,59021 claims |
| MerckJanuvia | $174 | $25,86427 claims |
| Boehringer IngelheimJardiance | $144 | $24,54546 claims |
| PfizerEliquis | $89 | $21,40518 claims |
| Lilly USA, LLCTrulicity | $201 | $11,94413 claims |
| Novo NordiskOzempic | $425 | $11,39112 claims |
| AbbVieSynthroid | $486 | $1,37517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Emporia
- Terry PolingWichita$24.2M
- Richard GloverNewton$19.6M
- Daniel DickersonLenexa$13.6M
- Patrick YaoOlathe$11.7M
- Michael RauschAugusta$8.1M
- Terry KleinWichita$5.9M
- Richard EgelhofWichita$4.1M
- Thomas KleinWichita$3.4M
- Troy HoldemanNewton$3.2M
- Stacy SlechtaNewton$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.